Addressing the health needs of the underserved

We give medicines, expertise and funding to help address diseases that primarily affect the underserved.

Neglected tropical diseases, malaria and tuberculosis

Neglected tropical diseases (NTDs), malaria and tuberculosis affect public health and the economic well-being of over 1 billion people worldwide. They disproportionately affect people in low- and middle-income countries.

As a result, ending these diseases by 2030 is a key sub-target for United Nations Sustainable Development Goal 3.

AbbVie was an original signatory to the London Declaration on Neglected Tropical Diseases, a global partnership among pharmaceutical companies, donors, endemic countries, and nonprofit organizations that aims to eliminate or control 10 NTDs.

Good Health and Wellbeing graphic

UN Sustainable Development Goal 3

Through our pro bono research program, AbbVie researchers have donated over 148,000 hours since 2013 to discovering and developing medicines for these diseases.

Two men talking in a store

A scientist’s retirement plan: Sterilize worms, eliminate neglected diseases

A chance to help people with the devastating disease onchocerciasis, or river blindness, brought two retirees back to the lab.

Read more

Access to essential medicines and care

We work closely with partners to help make medicines available where they are most urgently needed. For example, we have worked with the Medicines Patent Pool (MPP) to help provide access to medicines for HIV and HCV.

MPP provides access to medicines in low- and middle-income countries by granting qualified generic manufacturers royalty-free intellectual property licenses to make lower-cost versions of important medicines. AbbVie has three licensing agreements with MPP, providing royalty-free licenses to our intellectual property for these medicines.

Details of these agreements are available on the MPP website.

Medicine donations

We partner with global humanitarian organizations to supply our donated medicines to help people facing urgent health care needs.

We have seven ongoing medicine donation partnerships, through which we provide ongoing supplies of medicines to nonprofit organizations conducting long-term programs for chronically underserved populations. In addition, we often supply medicines to relief organizations for response to natural and humanitarian emergencies. We provide other periodic medicine donations to help relieve unmet medical needs in communities around the world.

Helping to expand health system capabilities

We know that addressing the health needs of the underserved requires a community-level approach. AbbVie and the AbbVie Foundation help to strengthen community health systems through programming and financial support. We focus on areas where our experience and expertise align with significant opportunity to improve public health, including HIV, HCV, neonatology
and pharmacovigilance.

Baylor College of Medicine International Pediatric AIDS Initiative (BIPAI)

In Romania and Malawi, the AbbVie Foundation supports the Baylor College of Medicine International Pediatric AIDS Initiative (BIPAI) to provide comprehensive HIV care and treatment. In 2018 alone, this program served over 31,000 people.

See the story

Two women being helped by a female doctor.

As new medicines become available in low- and middle-income countries, it’s critical that local health systems have capabilities support patient safety. We give funding and safety science expertise to initiatives working to strengthen pharmacovigilance systems in Asia, Africa and Latin America.

an older woman sitting next to a younger woman holding a baby

Every year, 15 million babies worldwide are born prematurely. Being born early can affect multiple aspects of development. In more than 20 countries, our ‘Good to Grow’ initiative convenes local stakeholders with the aim of improving standards of prevention, care, and support for premature infants.

A young man talking to a man and woman and pointing to a bulletin on the wall

The WHO has set a target to eliminate hepatitis C virus infection by 2030. We are joining the global hepatitis community in supporting a strategy called micro-elimination, targeted elimination in specific cities, regions or patient groups. In 2018, we launched over 20 projects in 17 countries.

See the story

Kenyan Chama cha Mamatoto (mother-child) groups

Many women in Kenya don’t have access to prenatal education or the ability to bring in income. Enter the Chama cha Mamatoto (mother-child) groups, started in 2012 as a pilot program by AMPATH, a partnership between Moi University School of Medicine, Moi Teaching and Referral Hospital (both in western Kenya), and a consortium of North American academic health centers led by Indiana University.

See the story